ClinicalTrials.gg

TargetBeta

NR3C1

nuclear receptor subfamily 3 group C member 1 · also GR, GRL · Nuclear receptor subfamily 3 group C

17 programs in company-led studies act on NR3C1, from 16 companies: 3 in phase 3, 12 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (16 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
DexamethasoneruleAbbViephase 417427 running–ChEMBL
BudesonideruleAstraZenecaphase 41678 running–ChEMBL
PrednisoneruleJohnson & Johnsonphase 4658 running–ChEMBL
MethylprednisolonerulePfizerphase 4235 running–ChEMBL
PrednisoloneruleSanofiphase 4343 running–ChEMBL
fluticasone furoateruleGlaxoSmithKlinephase 4972 running–ChEMBL
BeclomethasoneruleChiesi Farmaceuticiphase 4461 running–ChEMBL
dexamethasone phosphateruleEyegate Pharmaceuticalsphase 4211 running–ChEMBL
vamoroloneruleReveraGen BioPharmaphase 4111 runningNR3C2ChEMBL
TriamcinoloneruleResearch Insightphase 451 running–ChEMBL
betamethasone dipropionateruleLEO Pharmaphase 4270 running–ChEMBL
BetamethasoneruleLEO Pharmaphase 490 running–ChEMBL
relacorilantruleCorcept Therapeuticsphase 3223 running–ChEMBL
Triamcinolone AcetonideruleClearside Biomedicalphase 3202 running–ChEMBL
Cyproterone AcetateruleEurofarma Laboratoriosphase 342 runningAR, PGRChEMBL
org-34517rulePop Test Oncologyphase 241 running–ChEMBL
TQC3302Sino Biopharmaceuticalphase 110 runningADRB2, CHRM3the company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.